Skip to content

Mobile Smoking Cessation Intervention in Enhancing Cancer Outreach in Low-Income Adult Smokers

Project ACTION: Adult Smoking Cessation Treatment Through Innovative Outreach to Neighborhoods

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00948129
Enrollment
626
Registered
2009-07-29
Start date
2009-08-10
Completion date
2021-02-10
Last updated
2023-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoker, Current Every Day Smoker

Brief summary

This trial studies how well a mobile smoking cessation intervention works in enhancing cancer outreach in low-income adult smokers. Mobile smoking cessation intervention may help smokers quit or cut back on smoking, and help increase the range of cancer prevention services provided to low-income adult smokers.

Detailed description

PRIMARY OBJECTIVES: I. Compare the efficacy of three smoking cessation interventions targeting community based low-income uninsured and underinsured individuals in a group-randomized trial. II. Evaluate the role of quit motivation, nicotine withdrawal, risk perception, self-efficacy, social support, and negative affect as potential mediators of smoking abstinence. III. Compare the cost-effectiveness of the three treatment conditions. OUTLINE: Participants are randomized to 1 of 3 groups. GROUP I (STANDARD CARE): Participants undergo standard of care smoking cessation intervention consisting of brief advice to quit smoking, nicotine replacement therapy (NRT), and self-help written materials. GROUP II (ENHANCED CARE): Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number and supportive text messages daily for 12 weeks. GROUP III (INTENSIVE CARE): Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number, supportive text messages daily for 12 weeks, and a smoking cessation telephone call over 15 minutes weekly for 12 weeks. After completion of study, participants are followed up at 3, 6, and 12 months.

Interventions

OTHERLaboratory Biomarker Analysis

Correlative studies

BEHAVIORALSmoking Cessation Intervention

Undergo standard of care smoking cessation intervention

BEHAVIORALTelephone-Based Intervention

Undergo telephone based smoking cessation intervention

Undergo smoking cessation counseling

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Smoked at least 100 cigarettes in lifetime * English or Spanish speaking * Currently smoking at least 5 cigarettes a day, on average * Willing to set a quit smoking date within a week of the enrollment

Exclusion criteria

* Positive history of a medical condition that precludes use of the nicotine patch * Current use of nicotine replacement therapy (NRT) * Current use of other smoking cessation medications (e.g., Chantix or Zyban) * Pregnant or nursing * Enrolled in another smoking cessation study

Design outcomes

Primary

MeasureTime frameDescription
Smoking abstinence rateAt 12 monthsThe primary method of analysis will be mixed-model logistic regression.
Cost-effectivenessAt 12 monthsWill perform an incremental cost-effectiveness analysis by comparing the expected economic costs and clinical benefits of the three strategies. Will create a decision-analytic model using TreeAge Pro 2007 software to conduct the incremental cost-effectiveness analysis.

Secondary

MeasureTime frameDescription
Salivary cotinine levelsAt 12 monthsSalivary cotinine will be measured using the NicAlert test system.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026